Tumor-restricted loss of DR5 and TRAIL resistance in SzS patient CD4⁺ cells. (A) Cells from HD, patients with SzS and CTCL cell lines were exposed to increasing doses of soluble TRAIL. Viability was determined upon annexin-V/PI staining. One representative of 3 experiments. (B) Mean (± SD) expression of TRAIL-receptors in CD4⁺ cells from healthy donors (gray histogram, n = 10) and patients with SzS (black histogram, n = 16). *P < .05. (C) Representative TRAIL-receptor expression profile in HD and patients with SzS.